Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 19/20 | 0.55 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19375981 | 0.93 | APLNR (0.56) | APLNR | |
| SCHEMBL19376129 | 0.92 | APLNR (0.64) | APLNR | |
| SCHEMBL19376127 | 0.92 | APLNR (0.64) | APLNR | |
| SCHEMBL19376122 | 0.91 | APLNR (0.66) | APLNR | |
| SCHEMBL19376245 | 0.90 | APLNR (0.67) | APLNR | |
| SCHEMBL19376039 | 0.90 | APLNR (0.67) | APLNR | |
| SCHEMBL19375862 | 0.89 | APLNR (0.55) | APLNR | |
| SCHEMBL19375858 | 0.87 | APLNR (0.67) | APLNR | |
| SCHEMBL19375883 | 0.87 | APLNR (0.66) | APLNR | |
| SCHEMBL19375964 | 0.87 | APLNR (0.57) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433247-B1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-08 | — | — | EP | claimed |
| CN-109195963-B | 6-hydroxy-4-oxo-1, 4-dihydropyrimidine-5-carboxamides as APJ agonists | 百时美施贵宝公司 | 2021-04-23 | — | — | CN | claimed |
| US-10590113-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-17 | — | — | US | claimed |
| US-10106528-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-23 | — | — | US | claimed |
| EP-3433247-B1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-109195963-B | 6-hydroxy-4-oxo-1, 4-dihydropyrimidine-5-carboxamides as APJ agonists | 百时美施贵宝公司 | 2021-04-23 | — | — | CN | disclosed |
| US-10590113-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3433247-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | Bristol-Myers Squibb Company (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-10106528-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-23 | — | — | US | disclosed |
| WO-2017165640-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170275272-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275272-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | AP2A1, P2RX5, AP3M1 | APLNR 32/4885SCD5 513/4885 |
| US-10106528-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | AP2A1, P2RX5, AP3M1 | APLNR 32/4885SCD5 513/4885 |
| US-20170275272-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | AP2A1, P2RX5, AP3M1 | APLNR 32/4885SCD5 513/4885 |
| US-10590113-B2 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | AP2A1, P2RX5, AP3M1 | APLNR 32/4885SCD5 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.